Take a look at some of Monday's morning movers:

Amylin Pharmaceuticals - Bristol-Myers Squibb is buying Amylin for $31 per share, or $5.3 billion in cash . In a follow-on deal, AstraZeneca will pay Bristol-Myers $3.4 billion for the right to collaborate on developing Amylin drugs after the deal is complete.

Lincare Holdings - Lincare is being bought by Germany’s Linde for $4.6 billion in cash . Lincare is a specialist in home-based oxygen therapy, while Linde is a maker of industrial gases.

Ingram Micro - The technology distributor is buying wireless device company BrightPoint for $650 million in cash. Ingram is seeking to expand into the mobile market, which has higher profit margins than its core personal computer business.

Barclays - Chairman Marcus Agius has resigned , in the wake of the Libor probe into interest-rate fixing that resulted in Barclays paying more than $450 million in fines. Chief Executive Officer Bob Diamond is also said to be under pressure to resign, but has not done so.

Apple - The company is paying $60 million to China’s ProView Technology to settle a trademark dispute over the iPad name.

AZN News & Analysis

 Immune system cancer drugs tipped to be a $35 bln market - 22 May 2013 EDT

 AstraZeneca closes in on site for new home in Cambridge - 20 May 2013 EDT

 Impax Labs launches generic version of Zomig - 17 May 2013 EDT

 UPDATE 1-Cubist bid for Optimer before sale process began-sources - 15 May 2013 EDT

 RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices - 10 May 2013 EDT

 More AZN News